This company is no longer active
DP81 Stock Overview
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Diffusion Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.70 |
52 Week High | US$11.87 |
52 Week Low | US$5.25 |
Beta | 1.81 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | -53.28% |
3 Year Change | -65.66% |
5 Year Change | -98.49% |
Change since IPO | -99.38% |
Recent News & Updates
Recent updates
Shareholder Returns
DP81 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | 2.2% | -1.3% |
1Y | -53.3% | 38.4% | 4.2% |
Return vs Industry: DP81 underperformed the German Biotechs industry which returned 3.3% over the past year.
Return vs Market: DP81 underperformed the German Market which returned -9.8% over the past year.
Price Volatility
DP81 volatility | |
---|---|
DP81 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 5.4% |
Market Average Movement | 4.7% |
10% most volatile stocks in DE Market | 9.8% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DP81 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DP81's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 16 | Bob Cobuzzi | https://www.diffusionpharma.com |
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Diffusion Pharmaceuticals Inc. Fundamentals Summary
DP81 fundamental statistics | |
---|---|
Market cap | €12.52m |
Earnings (TTM) | -€13.98m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs DP81 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DP81 income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$14.99m |
Earnings | -US$14.99m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -7.35 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did DP81 perform over the long term?
See historical performance and comparison